Jordan J. Feld
Elite in Hepatitis C

Jordan J. Feld

Toronto, ON, CA 
Elite in Hepatitis C
Toronto, ON, CA 
OverviewLocationsClinical Research

Overview

Jordan Feld practices in Toronto, Canada. Mr. Feld is rated as an Elite expert by MediFind in the treatment of Hepatitis C. His top areas of expertise are Hepatitis, Hepatitis C, Hepatitis B, Liver Transplant, and Lung Transplant.

His clinical research consists of co-authoring 353 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 210 articles and participated in 3 clinical trials in the study of Hepatitis C.

Gender
Male

Locations

Toronto, ON, Canada
Other Locations
Toronto, Canada
Kitchener, ON, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Rapid HCV Test and Treat to Increase HCV Treatment Uptake Among People Who Use Drugs
Rapid HCV Test and Treat to Increase HCV Treatment Uptake Among People Who Use Drugs
Enrollment Status: Completed
Publish Date: February 07, 2025
Intervention Type: Other
Study Phase: Not Applicable
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.
Enrollment Status: Completed
Publish Date: February 28, 2024
Interferon Lambda for Immediate Antiviral Therapy at Diagnosis (ILIAD): A Phase II Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19
Interferon Lambda for Immediate Antiviral Therapy at Diagnosis (ILIAD): A Phase II Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19
Enrollment Status: Completed
Publish Date: December 13, 2023
Intervention Type: Drug, Other
Study Drug: Peginterferon Lambda-1A
Study Phase: Phase 2
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drugs: Lonafarnib, Ritonavir, PEG IFN-alfa-2a
Study Phase: Phase 3
TOGETHER-Toronto: A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter, Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19
TOGETHER-Toronto: A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter, Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19
Enrollment Status: Unknown
Publish Date: April 05, 2022
Intervention Type: Drug, Other
Study Drug: Peginterferon Lambda-1A
Study Phase: Phase 3
A Phase IIIb, Open-label, Multicentre, International Randomised Controlled Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir (300mg)/Pibrentasvir (120mg) in Chronic HCV Treatment naïve Patients Without Cirrhosis
A Phase IIIb, Open-label, Multicentre, International Randomised Controlled Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir (300mg)/Pibrentasvir (120mg) in Chronic HCV Treatment naïve Patients Without Cirrhosis
Enrollment Status: Completed
Publish Date: December 11, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

353 Total Publications

National hepatitis B and C estimates for 2021: Measuring Canada's progress towards eliminating viral hepatitis as a public health concern.
National hepatitis B and C estimates for 2021: Measuring Canada's progress towards eliminating viral hepatitis as a public health concern.
Journal: Canada communicable disease report = Releve des maladies transmissibles au Canada
Published: August 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Feld's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 26 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile